Modern prostate cancer management increasingly relies on integrated risk stratification that combines histological grading with genetic profiling, fundamentally changing how clinicians approach individual cases. Grade Groups (I through V) have superseded Gleason score alone, with Grade V tumours exhibiting less than 30 percent five-year recurrence-free survival—a stark contrast to Grade I outcomes. The clinical implications are profound: low-grade, genetically favourable tumours are candidates for active surveillance, potentially avoiding unnecessary intervention, while high-grade cases or those harbouring PTEN, TP53, or BRCA2 mutations demand multimodal therapy including surgery, radiation, and/or systemic treatment. This risk-adapted approach optimizes outcomes by matching treatment intensity to biological aggressiveness. Patients should understand that their individual tumour genetics—not age or general risk factors alone—increasingly determine treatment recommendations. For clinicians, incorporating molecular testing into routine diagnostic evaluation is becoming essential for precision oncology. Read the full article on GMJ Newsroom.
Was this article helpful?
